The Lawyer’s new China Elite report contains the most detailed research available on the PRC legal market and contains unparalleled insight into the country's leading law firms. They vary in size, practice focus and geographic coverage, but they all share one common quality – ambition... Read more
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
A quartet of US firms has won lead roles on Merck's $41bn acquisition of pharmaceuticals rival Schering-Plough.
Fried Frank Harris Shriver & Jacobson partners David Shine, Philip Richter, William Reindel and Damian Ridealgh led a team advising Merck on the deal. Wachtell Lipton Rosen & Katz partner Andy Brownstein advised Schering-Plough.
Merck is a longstanding Fried Frank client. In 2004 partners Shine, David Shapiro and Jonathan Lewis advised the pharmaceutical company on its acquisition of Aton Pharma.
On the Schering-Plough acquisition Shearman & Sterling New York-based partners Peter Lyons, Jessica Nielsen and Eliza Swann led the team advising Morgan Stanley as underwriter while Sullivan & Cromwell partners George Sampas and Stephen Kotran advised co-underwriter Goldman Sachs.
The deal comes at a time of consolidation in the pharmaceuticals industry.
Earlier this year The Lawyer reported that Cadwalader Wickersham & Taft partner Dennis Block led the firm's team that advised Pfizer on its $68bn takeover of rival Wyeth. Simpson Thacher & Bartlett partner Casey Cogut advised Wyeth on the deal.
Wachtell also had a role on the Wyeth deal, advising the company's board of directors.